Abstract
Background: Several studies have shown that religiosity has beneficial effects on health, mortality and pathological conditions; little is known about religiosity in Alzheimers disease and the progression of its cognitive, behavioral and functional symptoms. Our aim was to identify any relationship between religiosity and the progression of cognitive impairment and behavioral disorders in mild-moderate Alzheimers disease, and any relationship between the patients religiosity and the stress in caregivers. Materials and Methods: 64 patients with Alzheimers disease were analyzed at baseline and 12 months later using the Mini-Mental State Examination (MMSE), the Behavioral Religiosity Scale (BRS) and the Francis Short Scale (FSS). Caregivers were also questioned on the patients functional abilities (ADL, IADL), the behavioral disturbances (NPI), and on their stress (NPI-D, CBI). Patients were divided into 2 groups according to BRS: a score of < 24 meant no or low religiosity (LR), while a score of ≥24 meant moderate or high religiosity (HR). Findings: LR patients had worsened more markedly after 12 months in their total cognitive and behavioral test scores. Stress was also significantly higher in the caregivers of the LR group. Global BRS and FSS scores correlated significantly with variations after 1 year in the MMSE (r: 0.50), NPI (r:-0.51), NPI-D (r:-0.55) and CBI (r:-0.62). A low religiosity coincided with a higher risk of cognitive impairment, considered as a 3-point decrease in MMSE score (OR 6.7, CI: 1.8- 24.7). Interpretation: Higher levels of religiosity in Alzheimers dementia seem to correlate with a slower cognitive and behavioral decline, with a corresponding significant reduction of the caregivers burden.
Keywords: Religion, Alzheimer disease, Cognitive functions, Behavioral disturbs, Caregiver
Current Alzheimer Research
Title: Does Religiosity Protect Against Cognitive and Behavioral Decline in Alzheimers Dementia?
Volume: 7 Issue: 5
Author(s): A. Coin, E. Perissinotto, M. Najjar, A. Girardi, E.M. Inelmen, G. Enzi, E. Manzato and G. Sergi
Affiliation:
Keywords: Religion, Alzheimer disease, Cognitive functions, Behavioral disturbs, Caregiver
Abstract: Background: Several studies have shown that religiosity has beneficial effects on health, mortality and pathological conditions; little is known about religiosity in Alzheimers disease and the progression of its cognitive, behavioral and functional symptoms. Our aim was to identify any relationship between religiosity and the progression of cognitive impairment and behavioral disorders in mild-moderate Alzheimers disease, and any relationship between the patients religiosity and the stress in caregivers. Materials and Methods: 64 patients with Alzheimers disease were analyzed at baseline and 12 months later using the Mini-Mental State Examination (MMSE), the Behavioral Religiosity Scale (BRS) and the Francis Short Scale (FSS). Caregivers were also questioned on the patients functional abilities (ADL, IADL), the behavioral disturbances (NPI), and on their stress (NPI-D, CBI). Patients were divided into 2 groups according to BRS: a score of < 24 meant no or low religiosity (LR), while a score of ≥24 meant moderate or high religiosity (HR). Findings: LR patients had worsened more markedly after 12 months in their total cognitive and behavioral test scores. Stress was also significantly higher in the caregivers of the LR group. Global BRS and FSS scores correlated significantly with variations after 1 year in the MMSE (r: 0.50), NPI (r:-0.51), NPI-D (r:-0.55) and CBI (r:-0.62). A low religiosity coincided with a higher risk of cognitive impairment, considered as a 3-point decrease in MMSE score (OR 6.7, CI: 1.8- 24.7). Interpretation: Higher levels of religiosity in Alzheimers dementia seem to correlate with a slower cognitive and behavioral decline, with a corresponding significant reduction of the caregivers burden.
Export Options
About this article
Cite this article as:
Coin A., Perissinotto E., Najjar M., Girardi A., Inelmen E.M., Enzi G., Manzato E. and Sergi G., Does Religiosity Protect Against Cognitive and Behavioral Decline in Alzheimers Dementia?, Current Alzheimer Research 2010; 7 (5) . https://dx.doi.org/10.2174/156720510791383886
DOI https://dx.doi.org/10.2174/156720510791383886 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
EDITORIAL: Neuroprotection Mechanisms and their Potential Applications
Current Neuropharmacology Therapeutic Advances in the Treatment of Alzheimer's Disease: Present and Future
Current Drug Therapy Analysis of Functional Brain Images Using Population-Based Probabilistic Atlas
Current Medical Imaging NAD in Skin: Therapeutic Approaches for Niacin
Current Pharmaceutical Design Unique Coronary Artery Disease Differences in Women as Related to Revascularization
Current Medicinal Chemistry Docosahexaenoic Acid-Phosphatidylcholine Improves Cognitive Deficits in an Aβ<sub>23-35</sub>-Induced Alzheimer’s Disease Rat Model
Current Topics in Medicinal Chemistry Beneficial Effects of Bioactive Phospholipids: Genomic Bases
Current Nutrition & Food Science Proinflammatory Cytokines and Chemokines in Neonatal Brain Damage
Current Pediatric Reviews Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies
Current Pharmaceutical Design Progress and Promise of Nur77-based Therapeutics for Central Nervous System Disorders
Current Neuropharmacology Physical Activity Level and Motor Aptitude: Motor Domains and Identification Capacity of Brazilian Insufficiently Active Older Adults
Current Aging Science The HIV Pandemic: A Forgotten Crisis?
Current Drug Targets - Infectious Disorders Therapeutic Targets in Prostaglandin E2 Signaling for Neurologic Disease
Current Medicinal Chemistry Small Molecule Natural Products and Alzheimer’s Disease
Current Topics in Medicinal Chemistry Alpha-1-Antichymotrypsin: A Common Player for Type 2 Diabetes and Alzheimer's Disease
Current Diabetes Reviews Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Current Pharmaceutical Design The Pathophysiology of Heme in the Brain
Current Alzheimer Research Genetic Variations in CHRNA7 or CHRFAM7 and Susceptibility to Dementia
Current Drug Targets Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management
Current Neuropharmacology ABAD: A Potential Therapeutic Target for Aβ-Induced Mitochondrial Dysfunction in Alzheimers Disease
Mini-Reviews in Medicinal Chemistry